An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-CORT113176 in Healthy Male Subjects
Latest Information Update: 30 Nov 2021
Price :
$35 *
At a glance
- Drugs Dazucorilant (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Corcept Therapeutics
- 16 Nov 2021 Status changed from not yet recruiting to completed.
- 09 Aug 2021 New trial record